HPV治疗性多肽疫苗的研究进展  

Research progress of HPV therapeutic peptide vaccines

作　　者：封婕 高玲娟[2] 许豪勤[3] 吴玉璘 林宁[3] 闫林萍[1,2] 钟天鹰 

机构地区：[1]南京医科大学第四临床医学院,210004 [2]江苏省南京市妇幼保健院 [3]江苏省计划生育科学技术研究所

出　　处：《中国计划生育学杂志》2018年第1期63-69,共7页Chinese Journal of Family Planning

摘　　要：宫颈癌是女性最常见的癌症之一,人类乳头瘤病毒(HPV)是宫颈癌和宫颈上皮内瘤变(CIN)的主要病因。HPV感染和宫颈癌之间的因果关系促使以病毒癌基因蛋白E6、E7为靶抗原治疗高危HPV的疫苗得到发展。治疗性疫苗不同于预防性疫苗,其旨在诱导细胞介导的免疫反应,而不是产生中和抗体。本文聚焦治疗性多肽疫苗在HPV相关病变和癌症治疗中的发展,并回顾了增强疫苗效力的策略和最新的治疗性多肽疫苗的临床试验。与其他治疗性疫苗相比,多肽疫苗安全稳定,易于生产,但其免疫原性较差,且存在HLA型别限制。目前,通常使用佐剂增强疫苗的效力,应用重叠长肽疫苗解决主要组织相容性复合体特异性的问题。另外,HPV的其他蛋白的疫苗研究也取得了一定的进展,多肽疫苗的研究可以从E6、E7蛋白延伸到其他蛋白。Cervical cancer is one of the most common cancers in women, and is the fourth leading cause of cancer death in women worldwide. Human papillomavirus （HPV） is an etiological factor of cervical cancer and cervical intraepitheli- al neoplasia （CIN）. The correlation between HPV infection and cervical cancer has prompted the development of thera- peutic vaccines against high-risk HPV types targeting the viral oncoproteins E6 and E7. Therapeutic vaccines differ from preventive vaccines in that they are aimed at inducting cell-mediated immunity rather than producing neutralizing antibodies. This review focuses on therapeutic peptide vaccines in development for the treatment of HPV-associated le- sions and cancers. Furthermore, strategies to enhance vaccine efficacy and the latest clinical trials on therapeutic pep- tide vaccines are reviewed. Compared with other therapeutic vaccines, peptide vaccines are safe, stable, and easy to manipulate, but they have low immunogenicity and the restriction on the HLA types. At present, adjuvants are com- monly used to enhance the effectiveness of the vaccine, and overlapping long peptide vaccines maybe used for solving the problem of MHC specificity. In addition, the research of other proteins vaccine for HPV has got some progress. Thus, the study of therapeutic peptide vaccines can be extended from E6 and E7 to other proteins.

关 键 词：宫颈癌 人乳头瘤病毒 治疗性多肽疫苗 研究进展 

分 类 号：R737.33[医药卫生—肿瘤]